Bioluminescence Ventures Strengthens Senior Team with Appointment of Campbell Murray as Senior Partner

Veteran biotech investor and entrepreneur to drive strategic growth and portfolio development

SAN FRANCISCO--(BUSINESS WIRE)--Bioluminescence Ventures (“BLV”), a biotech venture firm investing in next-generation medicines to address unmet medical needs, today announced the appointment of Campbell Murray, M.D., MPP, MBA to the firm as a Senior Partner. Dr. Murray brings extensive leadership, clinical and operational experience from his years of working with high-growth companies as an investor, leader, entrepreneur and advisor.

“I am privileged and excited to welcome Campbell Murray to the Bioluminescence Ventures team," said Founding and Managing Partner Kouki Harasaki, Ph.D. "Campbell will work with our venture team to identify and assess mission-driven biotechnology companies within our focused disciplines. His background in medicine and wealth of life science expertise, from seed to exit, will be invaluable to our portfolio companies as they advance their therapeutic programs from bench to bedside."

Campbell Murray, M.D. joins Bioluminescence Ventures (BLV) as a Senior Partner, bringing over two decades of experience in venture capital, biotech operations, and clinical medicine. Most recently, Dr. Murray was a general partner at Agent Capital. Previously, he spent more than 16 years with Novartis Venture Fund (NVF), where as Managing Director he invested over $200 million across a portfolio that yielded 6 M&A exits and 11 IPOs. His entrepreneurial experience includes serving as President & Chief Operating Officer of Diabetes Free and Intima Bioscience, and he has served on the Board of Directors of 22 emerging biotechnology companies.

A Kauffman Fellow (Class 11), he holds a Bachelor of Human Biology and an MBChB (MD) from the University of Auckland Medical School. He also holds an MPP from Harvard's Kennedy School of Government and an MBA from Harvard Business School.

"I am thrilled to join Bioluminescence Ventures at such a pivotal time for innovation in the biotech sector," said Dr. Murray. "BLV's commitment to advancing groundbreaking therapies aligns with my passion for fostering transformative medical advancements. I look forward to leveraging my experience to support the growth of pioneering companies in our portfolio and contribute to BLV's mission of improving patients' lives through strategic investments in cutting-edge science."

About Bioluminescence Ventures (BLV)

Bioluminescence is a leading US biotechnology venture capital firm investing in the future of medicine. We are inspired by the accelerating pace of biomedical innovation and its recent impact on humanity. We are mission-driven – investing our time, energy, and capital into translating transformative science into next-generation medicines that will impact patients. The firm focuses investments on four areas: Breakthrough Biology, Drug Discovery Platforms, Genetic Medicines Platforms, and Computational Biology Platforms. For more information, please visit Bioluminescence.com and follow us on LinkedIn and X.